Table 1.
Expression of CD133 and/or SSEA-1 in Various Primary Human GBMs and Their Derivative Tumor Cells
| TSC Name |
Percent Expression at the Earliest Passages | Percent Expression during In Vitro Expansion | Percent Expression of Xenograft Tumors | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total CD133+ |
Total SSEA-1+ |
CD133+/ SSEA-1+ |
SSEA-1+ in CD133+ |
Passages | Total CD133+ |
Total SSEA-1+ |
CD133+/ SSEA-1+ |
SSEA-1+ in CD133+ |
Passages | Total CD133+ |
Total SSEA-1+ |
CD133+/ SSEA-1+ |
SSEA-1+ in CD133+ |
|||||||||
| (1) Established TSC/TIC Lines |
0308 | 38.2 | 57.9 | 17.3 | 45.3 | p5 | 22.2 ± 6.5 | 60.1 ± 17.5 | 12.0 ± 1.5 | 56.5 ± 12.3 | p10–13 | 10.2 ± 6.5 | 17.6 ± 14 | 2.5 ± 2.9 | 19.8 ± 16.3 | |||||||
| 0206 | 3.7 | 87.5 | 3.2 | 86.5 | P2 | 7.4 ± 1.3 | 64.7 ± 22.0 | 6.6 ± 1.3 | 89.2 ± 1.4 | p5–7 | 3.5 ± 0.2 | 63.5 ± 13.6 | 3.4 ± 0.4 | 97.7 ± 14.6 | ||||||||
| 0827 | 2.1 | 74.4 | 2.0 | 95.2 | P1 | 2.4 ± 2.5 | 46.0 ± 8.4 | 1.2 ± 1.2 | 50.2 ± 3.1 | p2–6 | 2.3 ± 0.4 | 38.3 ± 8.5 | 1.5 ± 0.1 | 65.8 ± 6.0 | ||||||||
| 1031 | 1.7 | 1.0 | ND | ND | P0 | 9.4 ± 8.4 | 52.4 ± 20.7 | 7.9 ± 8.4 | 74.2 ± 23.2 | p8–10 | 2.7 ± 1.0 | 31.2 ± 9.3 | 1.2 ± 1.1 | 40.2 ± 24.8 | ||||||||
| 0822 | 63.5 | 85.8 | 60.4 | 95.1 | P4 | 57.3 ± 15.5 | 87.6 ± 7.3 | 54.8 ± 14.0 | 95.8 ± 1.5 | p11–12 | ND | ND | ND | ND | ||||||||
| 0117 | 22.3 | 7.7 | 2.5 | 11.2 | P4 | 5.7 ± 0.7 | 45.0 ± 16.7 | 2.3 ± 0.5 | 41.0 ± 3.5 | p14–15 | ND | ND | ND | ND | ||||||||
| 0211 | 28.0 | 0 | 0 | 0 | p7 | 34.6 ± 10.8 | 0 | 0 | 0 | p7–15 | 33.8 ± 13.3 | 0 | 0 | 0 | ||||||||
| 1228 | 0 | 6.8 | 0 | 0 | p3 | 0 | 41.9 ± 9.0 | 0 | 0 | p7–19 | 0 | 8.8 ± 4.3 | 0 | 0 | ||||||||
| 0131 | 0 | 3.4 | 0 | 0 | p3 | 0 | 2.5 ± 1.9 | 0 | 0 | p8–14 | 0 | 3.1 ± 1.7 | 0 | 0 | ||||||||
| 0707 | 0 | 0.7 | 0 | 0 | p5 | 0 | 3.5 ± 1.3 | 0 | 0 | p6–10 | 0 | 2.8 | 0 | 0 | ||||||||
| 0905 | 0 | 56.6 | 0 | 0 | p1 | 0 | 86.6 ± 16.6 | 0 | 0 | p2–8 | 0 | 56.9 ± 27.3 | 0 | 0 | ||||||||
| 0909 | 0 | 3.0 | 0 | 0 | p1 | 0 | 94.2 | 0 | 0 | p2 | ND | ND | ND | ND | ||||||||
| (2) Freshly Isolated GBM Cells |
1106 | 10.8 | 18.1 | 7.9 | 73.1 | p0 | ||||||||||||||||
| K4 | 5.2 | 5.6 | 3.9 | 75.0 | p0 | |||||||||||||||||
| 447 | 10.4 | 70.5 | 6.7 | 64.2 | p0 | |||||||||||||||||
| 492 | 12.4 | 10.8 | 2.4 | 18.9 | p0 | |||||||||||||||||
| 453 | 8.5 | 18.7 | 5.3 | 62.3 | p0 | |||||||||||||||||
| 460 | 6.6 | 70.3 | 4.9 | 74.5 | p0 | |||||||||||||||||
| 1218 | 0 | 13.4 | 0 | 0 | p0 | |||||||||||||||||
| 449 | 0 | 5.9 | 0 | 0 | p0 | |||||||||||||||||
| 461 | 0 | 32.2 | 0 | 0 | p0 | |||||||||||||||||
| 0605 | 0 | 2.4 | 0 | 0 | p0 | |||||||||||||||||
| 0420RP | 0 | 63.3 | 0 | 0 | p0 | |||||||||||||||||
| 475 | 0 | 7.7 | 0 | 0 | p0 | |||||||||||||||||
GBM tumor lines were presented as two groups: (1) the established TSC/TIC lines that have been expanded in vitro and (2) acutely dissociated tumor cells isolated from primary patient GBMs that have not been expanded in culture (labeled as passage 0 [p0]). Due to the limited number of cells, the expression of CD133 and/or SSEA-1 was determined only in later passages in some of the established GBM lines. We reported the expression values at the earliest passage technically possible in these cases. Expression of CD133 and/or SSEA-1 was determined at various passages during the in vitro expansion phase as well as the xenograft tumors. ‘‘Total CD133+’’ or ‘‘Total SSEA-1+’’ indicates the percentage of the positive cells in the whole population. ‘‘CD133+/SSEA-1+’’ indicates the percentage of double-positive cells in the whole population. ‘‘SSEA-1+ in CD133+’’ indicates the percentage of double-positive cells out of the CD133+ cells. ND, not determined.